Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 3.09
NEPT's Cash to Debt is ranked higher than
63% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. NEPT: 3.09 )
NEPT' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 3.09

Equity to Asset 0.57
NEPT's Equity to Asset is ranked higher than
67% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NEPT: 0.57 )
NEPT' s 10-Year Equity to Asset Range
Min: -0.42   Max: 0.83
Current: 0.57

-0.42
0.83
F-Score: 3
Z-Score: 0.95
M-Score: -4.77
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -235.10
NEPT's Operating margin (%) is ranked higher than
65% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. NEPT: -235.10 )
NEPT' s 10-Year Operating margin (%) Range
Min: -116.18   Max: -10.96
Current: -235.1

-116.18
-10.96
Net-margin (%) -180.96
NEPT's Net-margin (%) is ranked higher than
66% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. NEPT: -180.96 )
NEPT' s 10-Year Net-margin (%) Range
Min: -156.23   Max: 3.09
Current: -180.96

-156.23
3.09
ROE (%) -45.54
NEPT's ROE (%) is ranked higher than
70% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. NEPT: -45.54 )
NEPT' s 10-Year ROE (%) Range
Min: -596.63   Max: 4.65
Current: -45.54

-596.63
4.65
ROA (%) -27.16
NEPT's ROA (%) is ranked higher than
74% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. NEPT: -27.16 )
NEPT' s 10-Year ROA (%) Range
Min: -82.24   Max: 2.5
Current: -27.16

-82.24
2.5
ROC (Joel Greenblatt) (%) -68.68
NEPT's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. NEPT: -68.68 )
NEPT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1925.98   Max: -13.27
Current: -68.68

-1925.98
-13.27
Revenue Growth (%) -7.90
NEPT's Revenue Growth (%) is ranked higher than
73% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: -1.90 vs. NEPT: -7.90 )
NEPT' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 32
Current: -7.9

0
32
EBITDA Growth (%) 162.10
NEPT's EBITDA Growth (%) is ranked higher than
100% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. NEPT: 162.10 )
NEPT' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 162.1
Current: 162.1

0
162.1
EPS Growth (%) 89.00
NEPT's EPS Growth (%) is ranked higher than
98% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. NEPT: 89.00 )
NEPT' s 10-Year EPS Growth (%) Range
Min: -47.7   Max: 97.9
Current: 89

-47.7
97.9
» NEPT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2012

NEPT Guru Trades in Q4 2012

Steven Cohen Sold Out
» More
Q1 2014

NEPT Guru Trades in Q1 2014

Jim Simons 20,200 sh (New)
» More
Q2 2014

NEPT Guru Trades in Q2 2014

Jim Simons 40,900 sh (+102.48%)
» More
Q3 2014

NEPT Guru Trades in Q3 2014

Jim Simons 42,300 sh (+3.42%)
» More
» Details

Insider Trades

Latest Guru Trades with NEPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.54
NEPT's P/B is ranked higher than
86% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. NEPT: 2.54 )
NEPT' s 10-Year P/B Range
Min: 1.94   Max: 40.88
Current: 2.54

1.94
40.88
P/S 10.41
NEPT's P/S is ranked higher than
82% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. NEPT: 10.41 )
NEPT' s 10-Year P/S Range
Min: 0.87   Max: 34.78
Current: 10.41

0.87
34.78
EV-to-EBIT -4.64
NEPT's EV-to-EBIT is ranked higher than
84% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NEPT: -4.64 )
NEPT' s 10-Year EV-to-EBIT Range
Min: -768.3   Max: 576.3
Current: -4.64

-768.3
576.3
Current Ratio 4.79
NEPT's Current Ratio is ranked higher than
73% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. NEPT: 4.79 )
NEPT' s 10-Year Current Ratio Range
Min: 0.4   Max: 5.93
Current: 4.79

0.4
5.93
Quick Ratio 3.54
NEPT's Quick Ratio is ranked higher than
69% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. NEPT: 3.54 )
NEPT' s 10-Year Quick Ratio Range
Min: 0.2   Max: 4.87
Current: 3.54

0.2
4.87

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 20.82
NEPT's Price/Net Current Asset Value is ranked higher than
76% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 34.97 vs. NEPT: 20.82 )
NEPT' s 10-Year Price/Net Current Asset Value Range
Min: 4.81   Max: 444
Current: 20.82

4.81
444
Price/Tangible Book 2.61
NEPT's Price/Tangible Book is ranked higher than
90% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. NEPT: 2.61 )
NEPT' s 10-Year Price/Tangible Book Range
Min: 2.38   Max: 40.71
Current: 2.61

2.38
40.71
Price/Median PS Value 1.36
NEPT's Price/Median PS Value is ranked higher than
80% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. NEPT: 1.36 )
NEPT' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 9
Current: 1.36

0.12
9
Earnings Yield (Greenblatt) -21.60
NEPT's Earnings Yield (Greenblatt) is ranked higher than
57% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. NEPT: -21.60 )
NEPT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 0.3
Current: -21.6

0.2
0.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NTB.Canada, NTU.Germany
Neptune Technologies & Bioressources Inc was incorporated on October 9, 1998. It is a biotechnology company engaged in the development, manufacture and commercialization of marine derived omega polyunsaturated fatty acids. It is engaged in the research, development and commercialization of products derived from marine biomasses for the nutraceutical and pharmaceutical industries. The Company has three segments structured in three distinctive legal entities: the first is producing and commercializing nutraceutical products (Neptune); development and commercialization of pharmaceutical products for cardiovascular diseases applications (Acasti); and development and commercialization of pharmaceutical products for neurological diseases applications (NeuroBioPharm). The Company produces omega 3 PUFAs through its patented process of extracting oils from Antartic krill, which omega 3 PUFAs are then sold as bulk oil to company's distributors who commercialize them under their private label in the U.S., European and Australian nutraceutical markets. Its products include Neptune Krill Oil and ECOKRILL Oil generally come in capsule form and serves as a dietary supplement to consumers.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK